date: 2021-11-30T11:56:00Z
pdf:unmappedUnicodeCharsPerPage: 17
pdf:PDFVersion: 1.7
pdf:docinfo:title: Modeling of Personalized Treatments in Colon Cancer Based on Preclinical Genomic and Drug Sensitivity Data
xmp:CreatorTool: LaTeX with hyperref
Keywords: colon cancer; personalized treatment; drug combinations
access_permission:modify_annotations: true
access_permission:can_print_degraded: true
subject: The current standard therapies for advanced, recurrent or metastatic colon cancer are the 5-fluorouracil and oxaliplatin or irinotecan schedules (FOxFI) +/- targeted drugs cetuximab or bevacizumab. Treatment with the FOxFI cytotoxic chemotherapy regimens causes significant toxicity and might induce secondary cancers. The overall low efficacy of the targeted drugs seen in colon cancer patients still is hindering the substitution of the chemotherapy. The ONCOTRACK project developed a strategy to identify predictive biomarkers based on a systems biology approach, using omics technologies to identify signatures for personalized treatment based on single drug response data. Here, we describe a follow-up project focusing on target-specific drug combinations. Background for this experimental preclinical study was that, by analyzing the tumor growth inhibition in the PDX models by cetuximab treatment, a broad heterogenic response from complete regression to tumor growth stimulation was observed. To provide confirmation of the hypothesis that drug combinations blocking alternatively activated oncogenic pathways may improve therapy outcomes, 25 models out of the well-characterized ONCOTRACK PDX panel were subjected to treatment with a drug combination scheme using four approved, targeted cancer drugs.
dc:creator: Marlen Keil, Theresia Conrad, Michael Becker, Ulrich Keilholz, Marie-Laure Yaspo, Hans Lehrach, Moritz Schütte, Johannes Haybaeck and Jens Hoffmann
dcterms:created: 2021-11-30T11:47:26Z
Last-Modified: 2021-11-30T11:56:00Z
dcterms:modified: 2021-11-30T11:56:00Z
dc:format: application/pdf; version=1.7
title: Modeling of Personalized Treatments in Colon Cancer Based on Preclinical Genomic and Drug Sensitivity Data
Last-Save-Date: 2021-11-30T11:56:00Z
pdf:docinfo:creator_tool: LaTeX with hyperref
access_permission:fill_in_form: true
pdf:docinfo:keywords: colon cancer; personalized treatment; drug combinations
pdf:docinfo:modified: 2021-11-30T11:56:00Z
meta:save-date: 2021-11-30T11:56:00Z
pdf:encrypted: false
dc:title: Modeling of Personalized Treatments in Colon Cancer Based on Preclinical Genomic and Drug Sensitivity Data
modified: 2021-11-30T11:56:00Z
cp:subject: The current standard therapies for advanced, recurrent or metastatic colon cancer are the 5-fluorouracil and oxaliplatin or irinotecan schedules (FOxFI) +/- targeted drugs cetuximab or bevacizumab. Treatment with the FOxFI cytotoxic chemotherapy regimens causes significant toxicity and might induce secondary cancers. The overall low efficacy of the targeted drugs seen in colon cancer patients still is hindering the substitution of the chemotherapy. The ONCOTRACK project developed a strategy to identify predictive biomarkers based on a systems biology approach, using omics technologies to identify signatures for personalized treatment based on single drug response data. Here, we describe a follow-up project focusing on target-specific drug combinations. Background for this experimental preclinical study was that, by analyzing the tumor growth inhibition in the PDX models by cetuximab treatment, a broad heterogenic response from complete regression to tumor growth stimulation was observed. To provide confirmation of the hypothesis that drug combinations blocking alternatively activated oncogenic pathways may improve therapy outcomes, 25 models out of the well-characterized ONCOTRACK PDX panel were subjected to treatment with a drug combination scheme using four approved, targeted cancer drugs.
pdf:docinfo:subject: The current standard therapies for advanced, recurrent or metastatic colon cancer are the 5-fluorouracil and oxaliplatin or irinotecan schedules (FOxFI) +/- targeted drugs cetuximab or bevacizumab. Treatment with the FOxFI cytotoxic chemotherapy regimens causes significant toxicity and might induce secondary cancers. The overall low efficacy of the targeted drugs seen in colon cancer patients still is hindering the substitution of the chemotherapy. The ONCOTRACK project developed a strategy to identify predictive biomarkers based on a systems biology approach, using omics technologies to identify signatures for personalized treatment based on single drug response data. Here, we describe a follow-up project focusing on target-specific drug combinations. Background for this experimental preclinical study was that, by analyzing the tumor growth inhibition in the PDX models by cetuximab treatment, a broad heterogenic response from complete regression to tumor growth stimulation was observed. To provide confirmation of the hypothesis that drug combinations blocking alternatively activated oncogenic pathways may improve therapy outcomes, 25 models out of the well-characterized ONCOTRACK PDX panel were subjected to treatment with a drug combination scheme using four approved, targeted cancer drugs.
Content-Type: application/pdf
pdf:docinfo:creator: Marlen Keil, Theresia Conrad, Michael Becker, Ulrich Keilholz, Marie-Laure Yaspo, Hans Lehrach, Moritz Schütte, Johannes Haybaeck and Jens Hoffmann
X-Parsed-By: org.apache.tika.parser.DefaultParser
creator: Marlen Keil, Theresia Conrad, Michael Becker, Ulrich Keilholz, Marie-Laure Yaspo, Hans Lehrach, Moritz Schütte, Johannes Haybaeck and Jens Hoffmann
meta:author: Marlen Keil, Theresia Conrad, Michael Becker, Ulrich Keilholz, Marie-Laure Yaspo, Hans Lehrach, Moritz Schütte, Johannes Haybaeck and Jens Hoffmann
dc:subject: colon cancer; personalized treatment; drug combinations
meta:creation-date: 2021-11-30T11:47:26Z
created: 2021-11-30T11:47:26Z
access_permission:extract_for_accessibility: true
access_permission:assemble_document: true
xmpTPg:NPages: 13
Creation-Date: 2021-11-30T11:47:26Z
pdf:charsPerPage: 4015
access_permission:extract_content: true
access_permission:can_print: true
meta:keyword: colon cancer; personalized treatment; drug combinations
Author: Marlen Keil, Theresia Conrad, Michael Becker, Ulrich Keilholz, Marie-Laure Yaspo, Hans Lehrach, Moritz Schütte, Johannes Haybaeck and Jens Hoffmann
producer: pdfTeX-1.40.21
access_permission:can_modify: true
pdf:docinfo:producer: pdfTeX-1.40.21
pdf:docinfo:created: 2021-11-30T11:47:26Z